002603:SZSEShijiazhuang Yiling Pharmaceutical Co., Ltd. Class A Analysis

Shijiazhuang Yiling Pharmaceutical is trading at CNY 15.23, well below its 20‑day (CNY 15.84), 50‑day (CNY 16.48) and 200‑day (CNY 17.15) moving averages, indicating a sustained bearish price trend. The RSI of 37.7 and a bearish MACD (line -0.38 vs signal -0.33) reinforce the short‑term downside pressure, while volume is slipping below its 10‑day average, suggesting waning buying interest.
Fundamentally the company remains solid: revenue grew 3.5% YoY to CNY 7.9 bn, gross margins sit at a healthy 65%, and cash on hand (CNY 2.43 bn) dwarfs its minimal debt (CNY 0.02 bn). The dividend yield of 5.2% with a payout ratio under 40% signals sustainability, and the forward PE of 13.97 is well under the industry average of 24.75. However, the DCF‑derived fair value of CNY 13.62 is below the current price, implying the stock may be modestly overvalued despite analyst targets around CNY 20.4.